LONDON Feb 2 Drugmaker AstraZeneca warned on Thursday that revenue and income would fall once more this 12 months as low cost generic variations of its ldl cholesterol drug Crestor proceed to hit gross sales.

The British group hopes that 2017 would be the earnings trough, however its restoration hinges on the success of latest medicines and outcomes from a intently watched medical trial testing a mix of two lung most cancers medicine, which buyers view as dangerous.

This 12 months it expects a low to mid single-digit share decline in income, with core earnings per share (EPS) declining by a low to mid-teens share in native foreign money phrases from 2016’s stage of $4.31. (Reporting by Ben Hirschler; Editing by David Goodman)

Source link


Please enter your comment!
Please enter your name here